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Phosphatidylinositol 3-kinase (PI3K) iso-
forms PI3K and PI3K are implicated in
platelet adhesion, activation, and aggrega-
tion, but their relative contribution is still
unclear or controversial. Here, we report
the first comparative functional analysis
of platelets from mice expressing a cata-
lytically inactive form of PI3K or PI3K.
We demonstrate that both isoforms were
similarly required for maximal activation
of the small GTPase Rap1b and for com-
plete platelet aggregation upon stimula-
tion of G protein–coupled receptors for
adenosine 5-diphosphate (ADP) or
U46619. Their contribution to these
events, however, was largely redundant
and dispensable. However, PI3K, but not
PI3K, enzymatic activity was absolutely
required for Akt phosphorylation, Rap1
activation, and platelet aggregation down-
stream of the immunoreceptor tyrosine-
based activation motif (ITAM)–bearing re-
ceptor glycoprotein VI (GPVI). Moreover,
PI3K was a major essential regulator of
platelet adhesion to fibrinogen and of
integrin IIb3-mediated spreading. These
results provide genetic evidence for a
crucial and selective role of PI3K in
signaling through GPVI and integrinIIb3.
(Blood. 2009;114:2193-2196)
Introduction
The phosphatidylinositol 3-kinase (PI3K) is implicated in platelet
activation downstream of G protein–coupled receptors (GPCRs),
immunoreceptor tyrosine-based activation motif (ITAM)–bearing
receptors, as well as integrins.1 The different PI3K isoforms are
grouped in 3 classes, I, II, and III. Class I PI3K includes the
p85-associated members PI3K, PI3K, and PI3K (class IA), as
well as the PI3K isoform (class IB). Although all class I members
are expressed in platelets, PI3K and PI3K are considered to play
a major role in platelet physiology,1,2 but their relative contribution
is still controversial.
PI3K is activated by G protein  dimers, and, in platelets,
it has been implicated in Rap1b activation and integrin IIb3–
supported aggregation downstream of the Gi-coupled P2Y12
adenosine 5-diphosphate (ADP) receptor.3,4 This model has
however been challenged by other studies, proposing a predomi-
nant role of PI3K rather than PI3K in ADP-induced platelet
activation.5,6 In addition, the finding that PI3K also functions
as a scaffold protein7 supported a model for a kinase-
independent contribution of PI3K in ADP-mediated platelet
activation.8
In platelets, PI3K is also activated upon stimulation of the
ITAM-bearing collagen receptor glycoprotein VI (GPVI)/FcR
-chain.9 Although there is evidence that a class IA member is
involved,10 its identity is still unknown. Similarly, integrin IIb3
recruitment activates PI3Ks. The involvement of a class II member
has been hypothesized,11 but a possible role for class I isoforms
clearly emerges from a more recent study.12
The specific contribution of PI3K and PI3K in platelet
activation has remained largely elusive, mainly because of the early
embryonic lethality caused by genetic ablation of PI3K in mice,13
and because the interpretation of the analysis of PI3K knockout
mice turned out to be complicated by the kinase-independent action
of this isoform.7
In this work we report the first comparative analysis of platelet
activation in mice homozygous for the kinase dead forms of PI3K
(PI3KKD) or PI3K (PI3KKD), in which lysine at positions 805 or
833, respectively, had been substituted with an arginine residue.
Our results demonstrate that while both isoforms are implicated in
signaling by GPCRs, PI3K plays a unique role in platelet
activation downstream of GPVI and integrin IIb3.
Methods
Generation and characterization of PI3KKD and PI3KKD mice has been
previously reported.7,14 Blood was withdrawn from the inferior vena cava of
anesthetized animals, and washed platelets were prepared as described.15
Platelet aggregation was measured in a lumiaggregometer and followed for
up to 5 minutes upon addition of ADP (in the presence of 200 g/mL
fibrinogen), U46619, or convulxin. Phosphorylation of Akt was evaluated
on whole platelet lysates by immunoblotting with anti–phospho-Akt
(Ser473) antibody, followed by reprobing of the membrane with anti-Akt
antibody (Cell Signaling Technology). Rap1b activation was measured by a
pulldown assay using glutathione S-transferase (GST)–tagged RalGDS-
RBD. Analysis of platelet adhesion and spreading on immobilized fibrino-
gen was performed on coated glass coverslips, and results were quantified
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by fluorescence microscopy analysis upon staining with tetramethylrhodamine
isothiocyanate (TRITC)–phalloidin (Sigma-Aldrich). Further details on the
source of the reagents and on the experimental procedures adopted are
reported in previous works.5,15,16 The use of mice for our experimental work
was approved by the Ethics Committee of the University of Pavia.
Results and discussion
Tail bleeding time was not altered in both PI3KKD and PI3KKD
mice (data not shown), indicating that activity of neither PI3K
isoforms is essential for global hemostasis. Expression of p110
and p85 was normal in PI3KKD platelets, as was expression of
p110 and p85 in PI3KKD platelets (supplemental Figure 1,
available on the Blood website; see the Supplemental Materials
link at the top of the online article). However, we observed that
expression of p110 in PI3KKD platelets and expression of p110
in PI3KKD platelets, albeit clearly evident, was reduced by
approximately 50% to 60%. Although the reason for this enzyme
instability is unclear, this finding is consistent with previous
observations in other tissues.14
ADP-induced platelet aggregation was clearly impaired, but
never suppressed, in both PI3KKD and PI3KKD mice (Figure
1Ai). The PI3K inhibitor TGX221 further reduced, but did not
abolish, ADP-induced aggregation of PI3KKD platelets. Similarly,
comparable defective ADP-induced Rap1b activation was observed in
both genotypes, although Rap1b activation largely occurred indepen-
dently of both PI3K and PI3K activity (Figure 1Aii). TGX221 did
not further significantly reduce Rap1b activation in either ADP-
stimulated PI3KKD platelets or PI3KKD platelets. Figure 1Aiii
also shows that ADP-induced Akt phosphorylation was completely
suppressed in both genotypes. This surprising and unexplained
observation is actually in line with previous independent genetic
and pharmacologic data,2,5,16,17 and it clearly indicates a complex
interplay between the 2 isoforms in ADP signaling. These observa-
tions demonstrate that ADP-induced Rap1b activation and aggrega-
tion are only partially regulated by PI3K and PI3K kinase
activity, and they question the role of Akt in these processes.
Figure 1. Analysis of platelet activation in PI3KKD and PI3KKD mice. ADP (A), U46619 (B), or convulxin (C) induced platelet aggregation (i), Rap1b activation (ii), and Akt
phosphorylation (iii) in wild-type (WT), PI3KKD (KD), and PI3KKD (KD) mice. (i) Platelet aggregation was stimulated by 1, 5, or 10 M ADP (in the presence of 200 g/mL
fibrinogen) or U46619, or with 50 and 100 ng/mL convulxin (CVX). The percentage of platelet aggregation was determined 5 minutes after addition of the agonist. Aggregation
of PI3KKD was also measured upon preincubation with 0.5 M TGX221 (a gift from Dr Peter R. Shepherd, University of Auckland, Auckland, New Zealand) for 5 minutes. For
each agonist, maximal aggregation induced by the highest dose of agonist was considered as 100%. In the case of CVX stimulation, the dose of 100 ng/mL was sufficient to
trigger maximal platelet aggregation (light transmission higher than 95%) under our experimental conditions. Results are the mean  SD of 3 (A-B) or 6 (C) different
experiments (where not visible, SD bar is masked by the mark). Traces are as follows: F, wild-type platelets; f, PI3KKD platelets; , PI3KKD platelets treated with TGX221;
, PI3KKD platelets. Analysis with t test performed at each dose of agonists revealed that aggregation of both PI3KKD and PI3KKD platelets stimulated with ADP or U46619
was always significantly different from that of wild-type platelets (P  .01). Upon stimulation with CVX, PI3KKD platelets showed significantly reduced aggregation relative to
wild-type platelets at both concentrations tested, whereas aggregation of PI3KKD platelets was significantly reduced relative to that of wild-type platelets only at 100 ng/mL
(P  .05). (ii) Analysis of Rap1b activation was performed upon platelet stimulation with 1 or 5 M ADP or U46619 or with 50 ng/mL CVX for 60 seconds. When indicated,
stimulation of platelets was also performed upon preincubation with 0.5 M TGX221 (	 TGX) for 5 minutes, while Rap1b activation induced by CVX was also analyzed in the
presence of 2 U/mL apyrase (APY). Active Rap1b was precipitated with GST-tagged RalGDS-RBD and visualized by immunoblotting with a specific antibody. Identical aliquots
of total cell lysates from each sample were also tested for the total Rap1b expression by immunoblotting. Quantitative analysis was performed by densitometric scanning of the
immunoblots. For ADP and U46619, variable results were obtained, and thus histograms summarizing the quantitative analysis of 3 different experiments for wild-type (f),
PI3KKD (), and PI3KKD ( ) platelets are reported. Statistically significant differences in Rap1b activation in the PI3KKD or PI3KKD versus wild-type platelets (t test,
P  .05) are indicated by *. For CVX-treated platelets, a representative immunoblot of 3 identical experiments is reported, as either a normal or a completely inhibited activation
of Rap1b was constantly observed. (iii) Wild-type, PI3KKD, and PI3KKD platelets were stimulated with 5 M ADP, 5 M U46619, or 50 ng/mL CVX for the indicated times.
When indicated, platelets were preincubated with 0.5 M TGX221 for 5 minutes before stimulation. Proteins from identical aliquots of whole-cell lysates were separated by
SDS-PAGE on a 10% acrylamide gel, transferred to polyvinylidene difluoride, and probed with anti–phospho-Akt (Ser473) antibody (top panels). Membranes were stripped and
then reprobed with anti-Akt antibody (bottom panels). Immunoblots representative of 3 different experiments giving identical clearcut results are reported.
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The limited and redundant contribution of PI3K and PI3K to
platelet activation by GPCR stimulation was even more evident
when U46619 was used as an agonist. In this case, inhibition of
platelet aggregation was reduced only by approximately 30% in
both genotypes, and there was no additional effect of TGX221 on
either PI3KKD platelets (Figure 1Bi) or PI3KKD platelets (data
not shown). The latter finding confirms the specificity of this
inhibitor. U46619-induced activation of Rap1b was dependent on
both PI3K and PI3K (Figure 1Bii). In fact, although at 1 M
U46619 activation of Rap1b was only minimally affected by
inactivation of PI3K, but was almost ablated in PI3KKD plate-
lets, upon stimulation with 5 M approximately 50% of Rap1b
activation was independent of either enzyme. In contrast, U46619-
induced Akt phosphorylation was exclusively promoted by PI3K,
as it was undetectable in PI3KKD platelets, but occurred normally
in PI3KKD platelets. Accordingly, TGX221 completely inhibited
Akt phosphorylation in both wild-type and PI3KKD platelets.
Once again, these results indicate that Akt is not a necessary
mediator of PI3K contribution to platelet activation.
Important differences between PI3KKD and PI3KKD mice
were found upon stimulation of the ITAM-bearing receptor GPVI
by convulxin. Aggregation of PI3KKD platelets was only slightly
reduced compared with wild type, but it was almost completely
suppressed in PI3KKD platelets (Figure 1Ci). Moreover, addition
of TGX221 to PI3KKD platelets completely abolished the residual
convulxin-induced aggregation. The predominant contribution of
PI3K in convulxin-promoted platelet activation was confirmed by
the analysis of Akt phosphorylation and Rap1b activation (Figure
1Cii-iii). Both of these events were completely undetectable in
stimulated PI3KKD platelets but occurred normally in PI3KKD
platelets. Moreover, convulxin-induced Akt and Rap1b activation
in PI3KKD platelets was completely suppressed by TGX221.
GPVI-promoted Rap1b activation is partially dependent on se-
creted ADP,18 and actually it was decreased in the presence of
apyrase. However, even in the presence of apyrase, convulxin-
induced activation of Rap1b was still dependent exclusively on
PI3K but not on PI3K enzymatic activity (Figure 1Cii). These
results indicate that the catalytic activity of PI3K, but not of
PI3K, is involved in GPVI signaling and is required for Akt
phosphorylation, Rap1b activation, and platelet aggregation.
Finally, we analyzed the involvement of PI3K and PI3K in
integrin IIb3-mediated outside-in signaling. An evident and
significant reduction of adhesion and spreading on immobilized
fibrinogen was observed in the PI3KKD but not in the PI3KKD
platelets (Figure 2A). Quantitative analysis confirmed that apparent
reduction of PI3KKD adhesion was not statistically significant, and
Figure 2. Analysis of integrin IIb3–mediated platelet adhesion
and spreading. Platelets from wild type (WT), PI3KKD (KD), and
PI3KKD (KD) mice were plated on glass coverslips coated with
fibrinogen for 10, 30, and 60 minutes. Nonadherent cells were
removed, and adherent platelets were fixed, permeabilized, and
stained with TRITC-conjugated phalloidin. Both platelet adhesion,
evaluated as number of counted adherent platelets, and platelet
spreading, as number of adherent cells with lamellipodia extension
were quantified by fluorescence microscopy analysis. Representative
images at 40
 magnification of adherent platelets from the 3 geno-
types are reported in panel A. The column on the right reports
enlarged images (100
 magnification) of adherent platelets after
60 minutes to better evidentiate differences in the morphology of
spreaded cells. Quantitative analysis of adhesion of wild type (f),
PI3KKD (), and PI3KKD ( ) platelets are reported in panels B and
C, respectively. Platelet spreading is expressed as percentage of
adherent platelets with lamellipodia. Data are the means  SD of
5 different experiments, where adherent and spreaded cells in 5 differ-
ent fields were counted in each experiment (*P  .05 vs wild-type
platelets).
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that, in contrast, the defect of PI3KKD platelet adhesion was more
pronounced and statistically significant both at an early time point
and late time points where a reduction of approximately 50% was
measured (Figure 2B). According to previous findings,12 we found
that catalytic inactivation of PI3K slowed the initial rate of
platelet spreading on fibrinogen, but this initial small defect, which
was not statistically significant, was completely recovered within
60 minutes (Figure 1C). In contrast, PI3KKD platelets were almost
completely unable to spread on fibrinogen at every time point
analyzed (Figure 1C).
In conclusion, our comparative analysis of murine platelets
expressing catalytically inactive forms of PI3K and PI3K
demonstrated that both of these isoforms are involved, at different
extents and with a complex interplay, in GPCR-mediated platelet
activation, suggesting the potential usefulness of double selective
inhibitors. In contrast, we have demonstrated that PI3K is
essential for the tyrosine phosphorylation-based signaling path-
ways triggered by GPVI or IIb3. PI3K has been recently
suggested as being mainly activated by GPCRs.19 Our data
demonstrate that PI3K is a common signaling platform shared by
both ITAM signaling and GPCRs, but they also indicate that it
plays a predominant role in ITAM- and integrin-mediated platelet
activation.
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